OpGen signs non-exclusive distribution deal with Fisher Healthcare for Unyvero platform in U.S.

CapForce Inc.

Fisher Healthcare becomes non-exclusive national distributor for Unyvero A50 platform alongside OpGen's direct U.S. sales.
Initial focus on FDA-cleared Unyvero LRT (BAL) cartridge for hospitalized pneumonia patients and RUO Unyvero UTI for UTIs.
Unyvero LRT is first FDA-cleared IVD for bacterial pneumonia and antimicrobial resistance markers.
Unyvero UTI pivotal trial completed; De Novo classification request submitted to FDA.
Deal aims to expand Unyvero commercial presence and drive revenue growth in the U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.